Lexology January 14, 2026
After failing to pass in the previous Congress, a revised version of the “BIOSECURE Act” (“the Act”) was signed into law by President Trump on December 18, 2025, as Section 851 of the National Defense Authorization Act (“NDAA”) for Fiscal Year 2026 (P.L. 119-60). The new law will restrict US federal procurement and grants involving biotechnology products or services provided by “biotechnology companies of concern” (“BCC”).
While amended and clarified in key areas, the Act follows the same basic prohibition as the original legislation, such that federal agencies must not enter into, extend, or renew any “contract” with an entity that uses “biotechnology equipment or services” from a BCC in performance of their federal contracts.
Below we summarize the scope...
Today's Sponsors
Today's Sponsor